Science
Bispecific design as an engineering discipline
At Bivalent Bio, we treat bispecific design as an engineering discipline. Every molecule begins with a clearly defined biological hypothesis, and every format decision — geometry, valency, linker chemistry, affinity ratios — is made to serve that hypothesis rather than the other way around.
Our approach
The right scaffold for each target pair
We work across multiple bispecific formats, including IgG-like architectures, tandem scFv constructs, and asymmetric heterodimers, selecting the right scaffold for each target pair.
Our discovery process integrates structural modelling, high-throughput screening, and developability assessment from the earliest stages, so molecules that progress are not only potent but manufacturable.
Three pillars
How we engineer for the clinic
Rational format selection
Target biology drives architecture. We do not force every programme into a single platform.
Developability by design
CMC-aware engineering from lead identification onwards. Stability, aggregation behaviour, and expression yield are evaluated alongside potency.
Translational rigour
In vivo PK, biodistribution, and mechanism-of-action work are built into early candidate selection.
Therapeutic areas
Where dual engagement matters most
Oncology
A focus on solid tumours where T-cell engagement and tumour-microenvironment modulation are central to durable response.
Immune-mediated disease
Selected programmes where dual engagement offers a clear mechanistic rationale across autoimmunity and inflammation.
Explore the programmes behind the science
See how our engineering approach translates into a focused clinical pipeline.